Organic Process Research & Development 2006, 10, 391−397
Full Papers
Concise Synthesis of a Selective r1-Adrenoceptor Antagonist
Terrence J. Connolly,* Michael Matchett, Patrick McGarry, Sunil Sukhtankar, and Jiang Zhu
STS Chemical SerVices, Chemical DeVelopment, Roche Palo Alto LLC, 3431 HillView AVenue,
Palo Alto, California 94304, U.S.A.
Scheme 1
Abstract:
An efficient synthesis of an adrenoceptor antagonist has been
developed and demonstrated in a pilot plant. A linear synthesis
that relied on a catalytic reduction of a rather insoluble
nitroaromatic proved to be a viable route. The active pharma-
ceutical ingredient (API) that contained an amidine functional
group was generated from the amino-containing precursor by
activation of dimethylacetamide (DMA) with phosphorus oxy-
chloride (POCl3). The reaction between DMA and POCl3 was
studied using ReactIR and was found to be a fast but not
instantaneous reaction. The iminium salt generated from DMA
and POCl3 had acceptable stability to allow for its use on a
pilot-plant scale; however, a trend towards decomposition was
revealed on the basis of in situ FTIR data. Formation of the
complex was evaluated in a reaction calorimeter (RC-1), and
the stability of the complex was probed with an Advanced
Reactive System Screening Tool (ARSST).
symptoms included antagonists displaying selectivity for R1A
and R1B adrenoceptor subtypes.5-7 Compound 1 was recently
selected as a potential clinical candidate, and larger quantities
of 1 were required to support preclinical studies.
Results and Discussion
The key step in the discovery synthesis is shown in
Scheme 1. This route relied on generating two late-stage
intermediates and coupling them in the final step to generate
1. Although this approach allowed for significant flexibility
during the discovery process, it was not suitable for the
preparation of large amounts of 1 due to the synthesis and
physical properties of 3 (Scheme 2).
Introduction
Benign prostatic hyperplasia (BPH) is a male urological
disorder characterized anatomically by enlargement of the
prostate gland due to cellular proliferation of prostatic tissue.
The symptoms of BPH can be classified as obstructive
(hesitancy, low flow, high residual volume) or irritative
(frequency, urgency, nocturia, reduced bladder capacity).
Clinical studies have shown R-1 adrenoceptor antagonists
to be effective in relieving both the obstructive and irritative
symptoms associated with BPH.1-3 Although subtypes of the
R-1 adrenergic receptors are known (R1A, R1B, and R1D),4
the alpha-1 blockers used to treat BPH currently are
nonsubtype selective and have the potential to cause car-
diovascular side effects such as postural hypotension and
dizziness. Clinical doses can be titrated against the side
effects although efficacy may be sacrificed.
The synthesis of 3 required several steps to assemble the
amidine functional group in the presence of the benzylic
amine. The sequence started with 4 and involved sequential
protection of the amine with tert-butylcarbonyl anhydride,
catalytic hydrogenation of the nitro group, condensation with
dimethylacetamide dimethylacetal (DMADMA), and removal
of the nitrogen protecting group. The absence of crystalline
or solid intermediates in the sequence used to prepare 3
would require telescoping the API synthesis from 4 to 1.
This route was not viewed as having any potential for a large-
scale synthesis. The expected result of such extensive
processing was a final product of unacceptable quality.
Once 1 was identified as a clinical candidate, a diversity-
driven synthesis was no longer important, and an efficient
route to 1 was essential. Regardless of the route to 1, a
method to prepare 2 was required and is shown in Scheme
3. Quinazolinedione 58 was converted to the dichloride 6
Efforts at Roche Palo Alto to develop new chemical
entities (NCE) for treating irritative and obstructive BPH
* Correspondence should be addressed to this author at current address:
Department of Process Chemistry, Celera, 180 Kimball Way, South San
(1) Djavan, B.; Marberger, M. Eur. Urol. 1999, 36, 1-13.
(2) Kumar, V. L.; Dewan, S. Int. Urol. Nephrol. 2000, 32, 67-71.
(3) Michelotti, G. A.; Price, D. T.; Schwinn, D. H. Pharmacol Ther. 2000, 88,
281-309.
(4) Hieble, J. P.; Bylund, D.; Clarke, D. E.; Eikenburg, D. C.; Langer, S. Z.;
Lefkowitz, R. J.; Minneman, K. P.; Ruffolo, R. R. Pharmacol. ReV. 1995,
47, 267-270.
(5) Becker, C. K.; Caroon, J. M.; Melville, C. R.; Padilla, F.; Pfister, J. R.;
Zhang, X. WO 02/053558, 2005.
(6) Chin, E.; Cournoyer, R. L.; Keitz, P. F.; Lee, E. K.; Lopez-Apia, F. J.;
Melville, C. R.; Padilla, F.; Weinhardt, K. K. WO 2005005397, 2005.
(7) Connolly, T. J.; Keitz, P. F.; Lee, E. K.; Li, J.; Lopez-Apia, F. J.; McGarry,
P. F.; Melville, C. R.; Nitzan, D.; O’Yang, C.; Padilla, F.; Weinhardt, K.
K. WO 2005005395, 2005.
(8) Connolly, T. J.; McGarry, P.; Sukhtankar, S. Green Chem. 2005, 7, 586-
589 2005.
10.1021/op050122h CCC: $33.50 © 2006 American Chemical Society
Published on Web 05/04/2006
Vol. 10, No. 3, 2006 / Organic Process Research & Development
•
391